TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Larimar Therapeutics Inc?
What does OpenAI free version (gpt-3.5-turbo) know about Larimar Therapeutics Inc?
Last request | 27.01.2024
(There is a high chance that below response is an AI hallucination) |
Well Known | No |
Description | Larimar Therapeutics Inc is a biotechnology company focused on developing novel treatments for rare genetic diseases. |
Most Notable Achievements | Larimar Therapeutics Inc has a strong pipeline of potential therapies that have shown promising results in preclinical studies. |
The Most Negative Fact | The company is relatively new and has not yet brought any products to market. |
Competition | None |
Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Larimar Therapeutics Inc?
Request date | |
Well Known | No |
Description | Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. |
Most Notable Achievements | The company is pioneering the development of a potential treatment for Friedreich's Ataxia, a rare genetic disease with no current cure. |
The Most Negative Fact | The company's lead product candidate, CTI-1601, received a clinical hold from the FDA in 2021, delaying its development. |
Competition | |
Share with friends |
What does Google AI (PaLM) know about Larimar Therapeutics Inc?
Last request | 27.01.2024 |
Well Known | no |
Description | Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. |
Most Notable Achievements | The company's lead product candidate, LARIMAR-01, is a novel, first-in-class, oral, small molecule inhibitor of the aryl hydrocarbon receptor (AHR) that is currently in Phase 1 clinical development for the treatment of patients with advanced solid tumors. |
The Most Negative Fact | The company has a limited financial history and has not yet generated any revenue. |
Competition | None |
What does Microsoft Bing AI know about Larimar Therapeutics Inc?
Well Known | No |
Description | rao tbe ti lIevf eaereooa veiicn sndaoed prrmpoeoncouunnigest.g oessLera Tfdtharsemictohtaenmclns ipeacl cri n ys gy |
Most Notable Achievements | smar hvth leussi osl paip ncisnrn etuasilec n g oti mtosautgaTanrie thpeenipIehcasitor Lnrlir lrpeifta is.ricn aethheodawps ep |
The Most Negative Fact | optTmvtgerpesu emi ywttau ib o a rnyeosnrlleha rc o tn a entykshhac dntya .do |
Competition | Nnoe |